Blue Jet Healthcare Q4FY25: Healthy Beat, Confident Outlook
Blue Jet Healthcare has delivered a strong Q4 finish to cap off FY25. With robust traction in pharma intermediates (PI) and APIs, the company posted results that beat expectations comfortably. Yes, contrast media intermediates did slow things down a little, but overall, the growth engine looks well-fuelled for the long haul.
What Clicked This Quarter?
The company reported Q4FY25 revenue of ₹340 crore, up 7% sequentially and 13% ahead of estimates. That’s a solid performance driven primarily by API and pharma intermediates.
Gross margins stood at 54.9%, improving both year-on-year (+160 bps) and quarter-on-quarter (+30 bps). Operating efficiency is clearly trending in the right direction.
But the biggest surprise came in profits—PAT came in at ₹110 crore, which is 168% higher YoY and 7% higher QoQ, beating estimates by a sharp 22%.
What the Management’s Betting On
Looking ahead, Blue Jet is leaning on two major levers:
- New product launches in the contrast media segment
- Consistent strength in core pharma intermediates and APIs
Together, these are expected to deliver a 26% revenue CAGR over FY25–28E. And that’s not all—EBITDA and adjusted EPS are expected to grow at 30% and 27% CAGR respectively in the same period.
So yes, the company is not just reacting—it’s proactively scaling.
What Needs a Closer Look?
While the core business delivered, one area did miss the mark—contrast media intermediates, which accounted for 30% of Q4 sales.
Revenue here was ₹100 crore, which was:
- Down 10% YoY
- Down 19% QoQ
- And 18% below estimates
This drag pulled down what could have been an even stronger quarter. But with new launches in the pipeline, this is likely a short-term blip, not a long-term concern.
Quick Snapshot: Q4FY25 Numbers
| Metric | Q4FY25 Performance | Movement |
|---|---|---|
Revenue | ₹340 crore | +7% QoQ |
Gross Margin | 54.9% | +30 bps QoQ |
PAT | ₹110 crore | +168% YoY, +7% QoQ |
Contrast Media Sales | ₹100 crore | ↓10% YoY, ↓19% QoQ |
At the current price of ₹770, the stock is trading at 26.6x P/E FY27E EPS, which is fair given its growth momentum. The revised Fair Value is ₹820, and the rating remains ADD.
For investors looking at scalable growth in pharma manufacturing—with a balance of consistency and upside—Blue Jet Healthcare continues to look attractive.
Disclaimer & Full Report
This feature is based on a synopsis of a research report issued by Kotak Securities Limited. For the full story (and disclaimers), make sure to check out the original sources:
Investments in securities market are subject to market risks, read all the related documents carefully before investing. This information is purely backed by KSL research analyst based on research recommendation. Kotak Securities Ltd has registration granted by SEBI, Enlistment as RA and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Registered Office: 27 BKC, C 27, G Block, Bandra Kurla Complex, Bandra (E), Mumbai 400051. SEBI Registration No. INZ000200137 (Member of NSE, BSE, MSE, MCX & NCDEX), Member Id: NSE-08081; BSE-673; MSE-1024; MCX-56285; NCDEX-1262. Research Analyst INH000000586; BSE Enlistment No: 5035 for compliance T&C and disclaimers, Visit https://ddei5-0-ctp.trendmicro.com:443/wis/clicktime/v1/query?url=https%3a%2f%2fbit.ly%2flongdisc&umid=818E14E7-34FE-7906-906B-8F0B1C42A394&auth=d2c41a7df2e2ef1fca42bbbefb1c825d24cf1548-36f3d1caa4f5ef82b030dac05eca909befcec775,
